DexCom, Inc. (DXCM) is set to announce its fiscal fourth-quarter earnings after the market closes on Feb. 12. Analysts expect a profit of $0.65 per share, up 44.4% from the year-ago quarter, and anticipate EPS of $2.06 for the full year, a 25.6% increase from the previous year. Despite underperforming the S&P 500 and Health Care Select Sector SPDR Fund, DXCM faces challenges such as an FDA warning letter, trade war concerns with China, and operational issues. However, the company is implementing new quality controls and shipping methods to address these issues.

Following its Q3 results, DXCM stock saw a 14.6% decline despite beating Wall Street expectations for adjusted EPS and revenue. Analysts remain bullish on DXCM stock, with a majority recommending a “Strong Buy” rating and an average price target of $85.20, indicating a potential upside of 22.2% from current levels.

Read more at Yahoo Finance: DexCom’s Q4 2025 Earnings: What to Expect